Search

Displaying results 2541 - 2550 of 10000 in total
  1. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology … [A253947,A253957] In clinical trials, it significantly reduced brain Aβ plaques compared to placebo.

  2. Drug

    Technetium Tc-99m oxidronate

    go.drugbank.com/drugs/DB09139
    ApprovedWithdrawn

    A radiopharmaceutical is defined as a medicinal formulation containing radioisotopes that are used in major clinical areas for diagnosis and/or therapy. … Technetium Tc-99m oxidronate, also known as 99mTc-methylene diphosphonate, is a radiopharmaceutical agent.

  3. Drug

    Anethole trithione

    go.drugbank.com/drugs/DB13853
    Approved

    hepatitis [L2388] and is marketed in certain countries like France, Germany, and China [A32614]. … for many of these aforementioned functions at this time and is only used in limited regions around the world.

  4. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead.

    International brands: Myrcludex B
  5. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients

    Synonyms: (R,R)-formoterolMixtures: AIRBIR 3/100 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL, 120 KPS, AIRBIR 3/100 MCG INHALASYON IÇIN TOZ IÇEREN KAPSÜL, 60 KPS
  6. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide

    Categories: P-glycoprotein substrates
  7. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

    Categories: 2-Amino-1-Phenylethanol Derivatives, Cytochrome P-450 Substrates
  8. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

    Categories: Heterocyclic Compounds, 1-RingSynonyms: Diphenyl(3-(1-piperidyl)propyl)carbinol, alpha,alpha-Diphenyl-1-piperidinebutanol
  9. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons

  10. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index